Page last updated: 2024-11-13

urolithin c

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

urolithin C: inhibits cell proliferation; from Epilobium sp. herbs; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

FloraRankFlora DefinitionFamilyFamily Definition
EpilobiumgenusA plant genus of the family ONAGRACEAE. The common name of fireweed is also used with other plants.[MeSH]OnagraceaeThe evening primrose plant family of the order Myrtales, subclass Rosidae, class Magnoliopsida. Flower parts are mostly in fours and the ovary is inferior.[MeSH]

Cross-References

ID SourceID
PubMed CID60198001
CHEMBL ID4754666
CHEBI ID174255
SCHEMBL ID15423100
MeSH IDM0594256

Synonyms (19)

Synonym
3,8,9-trihydroxybenzo[c]chromen-6-one
urolithin c
CHEBI:174255
SCHEMBL15423100
C73197
3,8,9-trihydroxy-6h-benzo[c]chromen-6-one
HHXMEXZVPJFAIJ-UHFFFAOYSA-N
urolithin-c
165393-06-6
AKOS030633041
3,8,9-trihydroxy-urolithin
mfcd20275232
DS-20037
HY-135897
CS-0116119
6h-dibenzo[b,d]pyran-6-one, 3,8,9-trihydroxy-
SY272011
DTXSID201318250
CHEMBL4754666

Research Excerpts

Overview

Urolithin C is a glucose-dependent activator of insulin secretion acting by facilitating L-type Ca2+ channel opening and Ca2+. influx into pancreatic beta-cells.

ExcerptReferenceRelevance
"Urolithin C is a glucose-dependent activator of insulin secretion acting by facilitating L-type Ca2+ channel opening and Ca2+ influx into pancreatic beta-cells. "( The ellagitannin metabolite urolithin C is a glucose-dependent regulator of insulin secretion through activation of L-type calcium channels.
Bayle, M; Cros, G; Crozier, A; Dall'Asta, M; Del Rio, D; Gautheron, G; Guichou, JF; Magous, R; Neasta, J; Oiry, C; Quignard, JF; Virsolvy, A; Youl, E, 2019
)
2.25

Bioavailability

ExcerptReferenceRelevance
" The results indicate that bioavailability of ellagitannins appears to be dependent on the composition of gut microbiota."( Effects of ellagitannin-rich berries on blood lipids, gut microbiota, and urolithin production in human subjects with symptoms of metabolic syndrome.
Aura, AM; Espín, JC; Kankainen, M; Kolehmainen, M; Leppänen, T; Maukonen, J; Moilanen, E; Nohynek, L; Oksman-Caldentey, KM; Poutanen, K; Puupponen-Pimiä, R; Seppänen-Laakso, T; Tómas-Barberán, FA; Törrönen, R, 2013
)
0.39
" Due to the not well-established bioavailability of ellagitannins, the mechanisms of observed therapeutic effects following oral administration still remain unclear."( Role of human gut microbiota metabolism in the anti-inflammatory effect of traditionally used ellagitannin-rich plant materials.
Granica, S; Kiss, AK; Melzig, MF; Piwowarski, JP; Schopohl, P; Stefańska, J; Zwierzyńska, M, 2014
)
0.4
"A pilot intervention study was conducted in human volunteers (n = 4) to establish the bioavailability of urolithins, which are the terminal end-products of ellagitannin metabolism by the gastrointestinal microflora."( Pilot walnut intervention study of urolithin bioavailability in human volunteers.
Gehres, N; Haubner, R; Owen, RW; Pfundstein, B; Ulrich, CM; Würtele, G, 2014
)
0.4
" Due to the questionable bioavailability of ellagitannins their gut microbiota metabolites-urolithins have come to be regarded as potential factors responsible for biological activities observed in vivo."( Urolithins, gut microbiota-derived metabolites of ellagitannins, inhibit LPS-induced inflammation in RAW 264.7 murine macrophages.
Granica, S; Kiss, AK; Moeslinger, T; Piwowarski, JP, 2015
)
0.42
"We investigated the effect of mixing soy protein isolate and pomegranate juice (PJ) on the bioavailability and metabolism of ellagitannins (ETs) in healthy volunteers."( Soy protein isolate does not affect ellagitannin bioavailability and urolithin formation when mixed with pomegranate juice in humans.
Heber, D; Henning, SM; Hsu, M; Lee, R; Li, Z; ManLam, H; Thames, G; Yang, J, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
ellagic acid degradation to urolithins011

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1683914Growth inhibition of Escherichia coli 0147:K89:K88 at 20 to 500 uM measured every 5 mins for 24 hrs by turbidometric analysis2020Journal of natural products, 12-24, Volume: 83, Issue:12
AID1683913Growth inhibition of Escherichia coli DSM 2840 at 20 to 500 uM measured every 5 mins for 24 hrs by turbidometric analysis2020Journal of natural products, 12-24, Volume: 83, Issue:12
AID1683908Induction of porcine IPEC-J2 cells monolayer development assessed as increase in transepithelial electrical resistance at 50 uM after 6 days by voltammetric method2020Journal of natural products, 12-24, Volume: 83, Issue:12
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's15 (71.43)24.3611
2020's6 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.76 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (4.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other20 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]